Boston Scientific and medical technology company Scivita Medical have signed a Strategic Agreement for Scivita’s Single-Use Percutaneous Choledochoscope. Through this business cooperation and distribution agreement, Scivita Medical and Boston Scientific plan to establish a long-term partnership in the commercialization, marketing and promotion of Scivita’s Single-Use Percutaneous Choledochoscope in China. Scivita Medical’s single-use videoscopes have covered multiple clinical departments at a high risk of cross-infection, such as Gynecology, Respiratory, Urological Surgery and Hepatobiliary Surgery. Many of its products have already been approved in China, the United States, European Union, Japan and other countries and regions.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BSX:
- Boston Scientific initiated with a Buy at UBS
- TD Cowen medical devices analyst to hold analyst/industry conference call
- Wells downgrades Edwards Lifesciences with Medtronic gaining share
- Boston Scientific price target raised to $55 from $50 at Argus
- Boston Scientific price target raised to $53 from $48 at Needham
